These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 16891463

  • 21. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A, Zeng Y, Ihnat M, Warnke LA, Green DW, Kisliuk RL, Lin FT.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5475-91. PubMed ID: 16039863
    [Abstract] [Full Text] [Related]

  • 22. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 23. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X, Chen Z, Tong L, Tan S, Zhou W, Peng T, Han K, Ding J, Xie H, Xu Y.
    Eur J Med Chem; 2013 Jul 01; 65():477-86. PubMed ID: 23770449
    [Abstract] [Full Text] [Related]

  • 24. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K, Hanahan D.
    J Clin Oncol; 2005 Feb 10; 23(5):939-52. PubMed ID: 15557593
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.
    Int J Cancer; 2012 Feb 15; 130(4):967-78. PubMed ID: 21445974
    [Abstract] [Full Text] [Related]

  • 26. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
    Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, Yang H, Zhang W, Gu Y, Ni L, Sai Y, Cui Y, Zhang M, Hong M, Sun J, Yang Z, Qing W, Su W, Ren Y.
    Cancer Biol Ther; 2014 Feb 15; 15(12):1635-45. PubMed ID: 25482937
    [Abstract] [Full Text] [Related]

  • 27. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U, Christofferson R.
    Pediatr Res; 2005 May 15; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [Abstract] [Full Text] [Related]

  • 28. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.
    Angiogenesis; 2009 May 15; 12(3):287-96. PubMed ID: 19544081
    [Abstract] [Full Text] [Related]

  • 29. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
    Gangjee A, Zaware N, Raghavan S, Ihnat M, Shenoy S, Kisliuk RL.
    J Med Chem; 2010 Feb 25; 53(4):1563-78. PubMed ID: 20092323
    [Abstract] [Full Text] [Related]

  • 30. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV.
    Oncogene; 2010 May 20; 29(20):2938-49. PubMed ID: 20208561
    [Abstract] [Full Text] [Related]

  • 31. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.
    Mol Cancer Ther; 2013 Sep 20; 12(9):1749-62. PubMed ID: 23804704
    [Abstract] [Full Text] [Related]

  • 32. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG.
    Ann Oncol; 2007 Sep 20; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [Abstract] [Full Text] [Related]

  • 33. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.
    Eur J Med Chem; 2013 Sep 20; 67():373-83. PubMed ID: 23900004
    [Abstract] [Full Text] [Related]

  • 34. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
    Hilberg F, Tontsch-Grunt U, Baum A, Le AT, Doebele RC, Lieb S, Gianni D, Voss T, Garin-Chesa P, Haslinger C, Kraut N.
    J Pharmacol Exp Ther; 2018 Mar 20; 364(3):494-503. PubMed ID: 29263244
    [Abstract] [Full Text] [Related]

  • 35. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1053-62. PubMed ID: 20103629
    [Abstract] [Full Text] [Related]

  • 36. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.
    Burkholder TP, Clayton JR, Rempala ME, Henry JR, Knobeloch JM, Mendel D, McLean JA, Hao Y, Barda DA, Considine EL, Uhlik MT, Chen Y, Ma L, Bloem LJ, Akunda JK, McCann DJ, Sanchez-Felix M, Clawson DK, Lahn MM, Starling JJ.
    Invest New Drugs; 2012 Jun 01; 30(3):936-49. PubMed ID: 21360050
    [Abstract] [Full Text] [Related]

  • 37. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.
    Cancer Res; 2003 Nov 01; 63(21):7301-9. PubMed ID: 14612527
    [Abstract] [Full Text] [Related]

  • 38. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A.
    Mol Cancer Ther; 2013 Jun 01; 12(6):913-24. PubMed ID: 23548264
    [Abstract] [Full Text] [Related]

  • 39. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S, Laird D, Cherrington JM, Knox SJ.
    Radiat Res; 2002 Jan 01; 157(1):45-51. PubMed ID: 11754641
    [Abstract] [Full Text] [Related]

  • 40. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P.
    Leuk Lymphoma; 2013 Jul 01; 54(7):1488-99. PubMed ID: 23121564
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.